

FY23 results

23 August 2023



Contents

01 Highlights

02 Financial results

03 Portfolio performance

04 Strategy

05 Annexure

Certain terms used throughout this presentation, including but not limited to, total gross income and revenue, investment income, estimated portfolio value (**EPV**), implied embedded value (**IEV**), and commitments are presented as non-IFRS information.

Further to this, commitments and EPV include all current investments (unconditional, conditionally funded, IC approved and investments disclosed as income yet to be recognised), whereas IEV excludes conditionally funded and IC approved investments.

Fund 1, Fund 5, and Fund 7 are not consolidated within the Group Consolidated Financial Statements; the residual interest in Fund 1 is recognised as an investment in associate and Fund 5 is brought in at the Group's attributable 20% share of income, assets, and liabilities with no associated non-controlling interests (**NCI**).

Throughout this document, Fund 5 and Fund 7 are presented at 100% values with the respective external investor's interests reflected as NCI. Fund 1 was deconsolidated on 31 May 2023; its metrics, effective from this date, are not disclosed in this presentation.

Further information on terms used in this presentation is available on slide 22 and definitions of key concepts are included in our Glossary <https://omnibridgeway.com/investors/omni-bridgeway-glossary> and should be read in conjunction with this presentation.

Significant growth in key drivers

For the 12 months ended 30 June 2023

Total gross income and revenue

\$333.0m +51%

From diversified sources
including secondary market sales

NPAT 2H23 turnaround v 1H23

+203%

FY23 NPAT \$0.9m

Cash and receivables¹

\$360.4m

Plus access to \$60m debt
Including \$129.2m OBL balance sheet

Commitments¹

\$544.2m +17%

Achieved a new record
and our FY23 target

Estimated portfolio value (EPV)¹

\$30.5bn +12%

After completions, removal
of impairments, disposals

Implied embedded value (IEV)¹

\$3.9bn +9%

\$1.0bn provisionally attributable to OBL,
excluding management fees and
potential performance fees⁴

Funds under management

~\$2.5bn

Across a balanced portfolio

EPV conversion rate

14%

Life to date completed investments²

ROIC

1.10x

Life to date completed investments²

IRR³

77%

1. Fund 5 is not consolidated within the Group Consolidated Financial Statements, here it is presented at 100%.

2. Reflects completions in Funds 1 to 5 and OBL balance sheet since inception, excluding partial secondary market sales. Reflects Fund 6 completions since OBE acquisition in 2019, including investments acquired and funded subsequently. Fund 1 includes metrics up to 31 May 2023, the date of its deconsolidation.

3. IRR information prior to FY12 is not available due to the difficulty in extracting it from legacy systems.

4. Further information on terms used in this presentation is available on slide 22 and definitions of key concepts are included in our Glossary <https://omnibridgeway.com/investors/omni-bridgeway-glossary>

Financial highlights

\$m	2H23	1H23	Change from 1H23	FY23	FY22	Change from FY22
Consolidated Group						
Litigation investments proceeds ¹	139.6	96.1	45%	235.7	217.3	8%
Cash proceeds on sale of participation in Fund 1 assets	47.7	–		47.7	–	
Litigation income proceeds (grossed up to include all Funds at 100%)	187.3	96.1	95%	283.4	217.3	30%
Third party income from sale of investment vehicle	–	86.6		86.6	–	
Less third party interest of Fund 5	(33.6)	(18.2)		(51.8)	(12.6)	
Litigation investments proceeds	153.7	164.5	(7%)	318.2	204.7	55%
Management fees	4.0	3.5	14%	7.5	5.7	31%
Interest revenue and other	5.1	2.2		7.3	10.6	
Total gross income and revenue	162.8	170.2	(4%)	333.0	221.0	51%
Litigation investments costs derecognised (non-cash)	(45.2)	(61.5)		(106.7)	(131.8)	19%
Derecognition of subsidiary and recognition of residual interest in Fund 1	(20.5)	–		(20.5)	–	
Reclassification to share of income from associates	0.2	(2.5)		(2.3)	–	
Third party share of sale of investment vehicle	–	(86.6)		(86.6)	–	
Total income (reflecting Consolidated Group)	97.2	19.6	396%	116.8	89.2	31%
Litigation investments – impairment and adverse costs	(9.4)	(3.7)	(154%)	(13.1)	(8.1)	(61%)
Amortisation of litigation investments – claims portfolio	(1.3)	(2.7)	52%	(4.0)	(5.7)	28%
Employee expenses	(35.0)	(39.0)	10%	(74.0)	(59.1)	(25%)
Other expenses	(14.5)	(17.6)	18%	(32.1)	(25.5)	(26%)
Fair value adjustments of financial assets and liabilities	2.6	–	100%	2.6	7.4	(65%)
Profit / (loss) before tax	39.6	(43.4)	191%	(3.8)	(1.8)	(111%)
Income tax benefit / (expense)	(8.6)	13.3	(165%)	4.7	8.3	(44%)
Profit / (loss) after tax	31.0	(30.1)	203%	0.9	6.5	(86%)

1. Data includes interest income on purchased claims. 1H23 and FY22 have been retrospectively adjusted to reflect this.

Financial summary

For the 12 months ended 30 June 2023

+\$61.1m NPAT 2H23 v 1H23 203% turnaround

reflecting improved income, lower expenses and signalling momentum heading into FY24

Significant improvement in total income 2H23 v 1H23

with 20 of 33 completions and strong return multiples occurring in 2H

\$283.4m litigation proceeds +30%

comprising \$235.7m investment completions and \$47.7m cash proceeds from sale of participation in Fund 1 assets

Net gain of \$27.2m

recognised from the deconsolidation of Fund 1

+31%% management fees on FY22

\$55.2m IYTBR

of which 43% converted in Aug-23

\$13.1m impairment expense and adverse costs

reflects the best estimate of the exposure across several investments

2H23 expenses -9% on 1H23

reflecting non-recurring items and initial savings from expense optimisation with a continued focus on cost efficiencies into FY24

Higher FY23 expenses predominately relate to the expansion of the platform, including increased headcount (224 v 199) and expenses which were subdued due to COVID-19 in FY22

Optimised capital and operational efficiencies



Build out of platform substantially complete, readying our business for anticipated future growth.



Strong improvement in operational efficiencies while scaling the team and expanding market reach.




Value created by investment managers (IMs) well in excess of our cost base.




This efficiency is expected to continue as the full contribution from our platform expansion is realised over the coming year.

\$m	FY23	FY22	Change
Efficiency ratios			
EPV / investment manager	341	279	22%
New investment EPV / investment manager	138	119	16%
Management fees ¹ / cash operational expenses ²	16%	20%	(20%)
Total expenditure ² / IEV	3%	2%	50%
Working capital ratio	2.6:1	2.3:1	13%
Headcount	224	199	13%
Number of locations	26	23	13%
EPV	30,475	27,202	12%

EPV managed per IM (\$m)



EPV generated per IM (\$m)



1. Includes management and servicing contribution from Fund 6, which is recognised as an equity contribution.

2. Excluding amortisation, impairments, adverse costs, interest and LTIP.

Securing portfolio growth to generate future income

Highlights

Financial results


Portfolio performance

Strategy

Annexure


Investments carrying value¹

\$741.8m




EPV¹

\$30.5bn



Commitments¹

\$544.2m



1. Fund 5 is not consolidated within the Group Consolidated Financial Statements, here it is presented at 100%.

2. Investment deployments include capitalised overheads and investment updates.


3. Following the sale of a participation in Fund 1 assets which completed on 31 May 2023, Fund 1 has been derecognised within the Group Consolidated Financial Statements. HC 1 LLC was disposed on 31 December 2022 and derecognised from the Group Consolidated Financial Statements.

4. Other includes foreign currency adjustments and impairments (that were primarily recorded in prior years and completed in FY23).

Balanced and diversified portfolio¹


- Consistent with mitigating concentration risk, the average investment size across the portfolio is \$1.5 m (\$0.8m for OBE investments, \$2.3m for all other investments).
- The 10 largest investments represent 22% of the total portfolio EPV compared to 35% four years ago, and 28% last year, with an anticipated continuation of this trend.
- We continue to seek out partial sale and co-funding opportunities for our larger deals and areas of increased exposure.
- Further activity expected in the secondary market, to de-risk mature assets and realise embedded value ahead of key milestones.

EPV by region




Balanced portfolio with growth potential in all regions.

EPV by investment type




Class actions and group claims represent 26% of our portfolio (14% Australia, 12% RoW).

EPV by funding source



Diversified funding sources whereby investments are funded through dedicated investment vehicles with global co-investors and joint venture structures.

EPV by case concentration



Across all funds, the 10 largest cases are spread across Funds 2&3, Fund 4 and Fund 5, with no balance sheet exposure.

For investments in cost shifting jurisdictions, we have after-the-event (ATE) insurance in place for adverse costs orders.

1. Fund 5 is not consolidated within the Group Consolidated Financial Statements, here it is presented at 100%.

2. Includes appeal, commercial and corporate funding.

Portfolio summary

At 30-Jun-23	Amounts attributable to NCI			Amounts attributable to Omni Bridgeway		Current funded investments ¹				Completed investments ²						
	Committed	Capital	Returns	Capital	Fees	#	Average duration	EPV	IEV	#	Average duration	EPV	EPV conversion rate	Success rate \$ weighted average	ROIC	IRR
Fund 1										35	3.5 yrs	\$2,023m	11%	69%	0.38x	12%
Funds 2&3 ²	100%	\$64m	\$56m	\$33m	\$8m	23	4.4 yrs	\$3,218m	\$483m	18	1.9 yrs	\$609m	16%	43%	0.91x	89%
Fund 4	86%	\$196m	-	\$49m	-	40	1.4 yrs	\$9,151m	\$1,373m	11	1.3 yrs	\$2,425m	4%	51%	(0.16x)	(18%)
Fund 5 ³	85%	\$179m	-	\$45m	-	57	1.6 yrs	\$9,874m	\$1,481m	13	1.7 yrs	\$1,137m	7%	76%	1.05x	54%
Fund 6 ⁴	100%	\$142m	-	\$7m	-	146	7.4 yrs	\$3,687m	\$553m	230	3.2 yrs	-	19%	80%	3.07x	177%
Fund 7 ³	4%	\$5m	-	<\$1m	-	-	-	-	-	-	-	-	-	-	-	-
Fund 8	4%	-	-	-	-	3	0.4 yrs	\$53m	\$8m	-	-	-	-	-	-	-
Funds total		\$586m	\$56m	\$134m	\$8m	269	4.9 yrs	\$25,983m	\$3,898m							
Balance sheet ⁵		-	-	-	-	5	8.3 yrs	\$31m	\$5m	196	3.0 yrs	\$5,455m	20%	78%	1.64x	80%
Total		\$586m	\$56m	\$134m	\$8m	274	5.0 yrs	\$26,014m	\$3,903m							

- **Fund 1** – Following the sale of a participation in Fund 1 assets which completed on 31 May 2023, the residual interest in Fund 1 is recognised as an investment in associate within the Group Consolidated Financial Statements. As such, Fund 1 metrics from 31 May 2023 are not disclosed.
- **Funds 2&3** – in harvest mode with NCIs continuing to have priority – these first generation structures will provide a substantial back-end return attribution in future periods.
- **Fund 4 and Fund 5** upsizing progressing well with ~US\$400m to US\$600m first close from existing investors expected in 1H24, followed by a potential second close with new investors. The Fund 4 performance metrics are impacted by a small number of completions, several of which have been both large and negative. With partial completions prior to and one completion since 30 June 2023, the performance metrics have improved to 0.05x ROIC and 7% IRR. Whilst these metrics remain lower than our historical performance, we are confident that with further successful outcomes the performance metrics will improve materially.
- **Fund 6** – in harvest mode with EMEA merits investment opportunities now funded by Fund 5 and global enforcement investment opportunities will flow to Fund 8 once closed.
- **Fund 7** – being restructured and discontinued.
- **Fund 8** – current investments are warehoused on OBL balance sheet until Fund 8 is fully established in 1Q24.


1. Includes current unconditional investments and those disclosed as income yet to be recognised.
2. Reflects completions in Funds 1 to 6 and OBL balance sheet since inception, excluding partial secondary market sales. Fund 1 includes metrics up to 31 May 2023, the date of its deconsolidation.
3. Fund 5 and Fund 7 are not consolidated within the Group Consolidated Financial Statements, here they are presented at 100%.
4. Fund 6 distribution profile is current at 31 March 2023. For current funded and completed investments, data is current at 30 June 2023. As a large portion of the acquired assets did not have assigned EPV, total EPV is not available. The conversion rate relates to the portion of the portfolio that had assigned EPV.
5. IRR information prior to FY12 is not available due to the difficulty in extracting it from legacy systems.

IEV is based on the realisation of the current unconditionally funded portfolio, utilising a normalised 15% EPV conversion rate.

Estimated value
from future completions

\$30.5bn
EPV

Estimated Portfolio Value¹




1. Includes all current investments (unconditional, conditionally funded, IC approved and investments disclosed as income yet to be recognised).
2. Includes current unconditional investments and those disclosed as income yet to be recognised.
3. Based upon OBL equity co-investment income rights.
4. Further information on the provisional attribution of IEV, estimated management fees and potential performance fees used in this presentation is available on slide 22 and definitions of key concepts are included in the Glossary at <https://omnibridgetway.com/investors/omni-bridgeway-glossary>.
5. Based on the Group historic 1.1x ROIC and achieving 20% IRR hurdle of completed investments.

Management fees¹

\$m	FY19	FY20	FY21	FY22	FY23	FY24F
Fund 1	n/a	n/a	n/a	n/a	n/a	
Fund 4	\$0.1m	\$1.2m	\$2.0m	\$2.6m	\$3.4m	
Fund 5	\$0.0m	\$0.2m	\$0.9m	\$2.0m	\$2.7m	
Funds 6&7	n/a	\$6.5m	\$14.6m	\$10.5m	\$10.1m	
Fund 8	n/a	n/a	n/a	n/a	n/a	
Total	\$0.1m	\$7.9m	\$17.5m	\$15.1m	\$16.2m	~\$22m

Fund 4 and Fund 5 management fees collected



- Includes management fees derived from Investment Management Agreements with the investors in Fund 4, Fund 5 and Fund 7².
- Includes management and servicing contribution from Fund 6 which is recognised as equity contributions.
- In addition, subject to returning investors' capital and preferred return, Funds 2&3 have accrued ~\$7.6m life to date management fees (payable from and subject to future proceeds, which are not reflected in the Group Consolidated Statement of Comprehensive Income).
- FY24 forecast management fees include:
 - Nominal fee for the ongoing management of Fund 1 post deconsolidation.
 - Fund 4 and Fund 5 ongoing management fees, considering similar terms in Funds 4 and 5 series II agreements.
 - Receipts from a cost coverage agreement as part of expected Fund 8 debt facility offsetting reduced Fund 6 management fees.
 - Implies a cost coverage ratio of >20%.
- Management fees are expected to continue to increase into the future in line with continued increase in deployed funds.

1. Further information on terms used in this presentation is available on slide 22 and definitions of key concepts are included in the Glossary at <https://omnibridgeway.com/investors/omni-bridgeway-glossary>.

2. Fund 7 is being restructured and discontinued.

Potential performance fees of funded portfolio¹

\$m		Group historic	-0.25x sensitivity	+0.25x sensitivity
ROIC assumption				
ROIC		1.10x	0.85x	1.35x
IEV- gross proceeds of Fund 4 and Fund 5		2,854	2,854	2,854
Return of investor capital (1.1x ROIC)		1,359	1,543	1,214
Profit		1,495	1,311	1,640
Profit (NCI)		1,196	1,049	1,312
Performance fees if fund profits are below the 8% IRR hurdle	0% of NCI profit	-	-	-
Performance fees over the part of fund profits up to 20% IRR	20% of NCI profit	239	210	262
Performance fees over the part of fund profits above 20% IRR	30% of NCI profit	Plus additional performance fee depending on ultimate IRR achieved		

- IEV is derived from the attribution table on page 15.
- ROIC is assumed to be in line with historic track record.
- If Funds 4 and 5 achieve an IRR in line with our historic track record of 77%, OBL would be eligible to receive performance fees in the high 20% range.
- Hurdles calculations consider fund administration costs including management fees (which have not been included in this illustration).
- Funds 4 and 5 performance fee calculations are independent of each other and may or may not generate a performance fee depending on the performance of each individual fund.
- In accordance with the income recognition accounting rules, we have not yet recorded any performance fees for Funds 4 and 5 in our earnings.
- Completions from future commitments would add additional performance fees to those presented here.

1. Further information on terms used in this presentation is available on slide 22 and definitions of key concepts are included in the Glossary at <https://omnibridgeway.com/investors/omni-bridgeway-glossary>.

Outlook

For personal use only

We are an alternative asset manager and investor in litigation and enforcement assets, a class that is typically uncorrelated with economic cycles and macro events.

We have strengthened core facets of our business and continue to set the highest industry standards as we transition to the next phase of our strategy.

We have a strong platform for growth and a balanced portfolio that is delivering results amidst a developing regulatory landscape.

Our FY24 goals include:

- Achieving \$625m new commitments or equivalent value through improved pricing and attribution terms.
- Exploring transition to or adding fair value reporting.
- Finalising the establishment of Fund 8, our new global enforcement fund.
- Increasing FUM via first closing of series II of Fund 4 and Fund 5 and potential launch of new funds.
- Continued focus on cost coverage improvement initiatives.
- Accelerating realisations and mitigating risk through secondary market transactions.
- Moderately expanding the UK team to increase our presence in the second largest litigation finance market.
- Aiming for ~\$95m of cash operational expenses

Medium term target

- \$1bn annual new commitments or equivalent value through improved pricing and attribution terms.

Key business performance drivers

- Optimising the volume vs. pricing trade-off
- Velocity in investment completions
- Secondary market sales
- Portfolio optimisation
- Sustained improvement in operational efficiencies and cost coverage

For personal use only

Annexure

Provisional attribution from estimated future completions¹

\$1.0bn of IEV provisionally attributable to OBL, excluding estimated management fees and potential performance fees, is based on the realisation of the current unconditionally funded portfolio and utilising a normalised 15% EPV conversion rate.

At 30-Jun-2023 \$m	Possible completion period (PCP)					Sensitivity analysis		
	FY24	FY25	FY26	FY27+	TOTAL	EPV conversion rate to IEV		15% EPV conversion rate
						10%	20%	PCP delay of 12 months
Funded EPV	4,954	6,959	4,501	9,600	26,014	26,014	26,014	26,014
	IEV at 15% EPV conversion rate							
Balance sheet	3	-	1	1	5	3	6	5
Funds 2&3	163	189	11	120	483	322	644	483
Fund 4 ²	186	353	403	431	1,373	915	1,830	1,373
Fund 5 ^{2,3}	328	377	162	614	1,481	987	1,975	1,481
Fund 6 ^{2,4}	62	124	97	270	553	369	737	553
Fund 8	1	1	2	4	8	5	11	8
Total IEV	743	1,044	676	1,440	3,903	2,601	5,203	3,903
IEV provisionally attributable to OBL	133	334	156	380	1,003	621	1,373	973

1. Further information on terms used in this presentation is available on slide 22 and definitions of key concepts are included in the Glossary at <https://omnibridgeway.com/investors/omni-bridgeway-glossary>.

2. Excluding performance fee entitlement.

3. Fund 5 is not consolidated within the Group Consolidated Financial Statements, here it is presented at 100%.

4. Utilises NCI's historic share of proceeds, being a blend of A,B, C, D investment specific waterfalls.

Structure of Funds¹

- If an investment is successful, the defendant will pay an agreed amount to the claimant's lawyers trust account.
- The lawyer will deduct the fees owing to the Group and pay the balance of funds to the client.
- If the claim fails, the Group is responsible for paying the counterparty's costs on the terms agreed with the client, if it is not covered by After The Event or Adverse Cost insurance.
- In addition, damages are not always awarded in cash. Investment Managers require the ability to appraise non-cash collateral when pricing the risks of an investment prior to the funding decision, and require the ability to collect varying forms of collateral for monetisation.
- The Group has an established track record of identifying, appraising and collecting non-cash collateral in a variety of jurisdictions.

	Funds 2&3	Fund 4	Fund 5	Fund 6
Type	European whole of fund	American deal by deal	American deal by deal	Hybrid whole of fund
Waterfall	- Investor capital - Investor preferred return - Investor undrawn fee - Group management fee - Group capital - Profit distribution: Group 80% Investor 20%	- Investor capital (including the Group) - Hurdle IRR 8% - Catch-up - Up to 20% IRR, 80% to investors (incl the Group) 20% performance fee - Above 20% IRR, 70% to investors (incl the Group) 30% performance fee	- Investor capital (including the Group) - Hurdle IRR 8% - Catch-up - Up to 20% IRR, 80% to investors (incl the Group) 20% performance fee - Above 20% IRR, 70% to investors (incl the Group) 30% performance fee	- Investor capital (including the Group) - Hurdle IRR 10% - Catch-up - Up to 20% IRR, 80% to investors (incl the Group) 20% performance fee - Above 20% IRR, 70% to investors (incl the Group) 30% performance fee Enforcement investments - Investor capital - Hurdle IRR 20% - Profit distribution (Group 100%)
Management fee	Part of waterfall return	Paid quarterly	Paid quarterly	As called
Capital recycling	Not permitted	Permitted	Permitted	Permitted

1. Fund 1 was deconsolidated on 31 May 2023. The residual interest in Fund 1 is recognised as an investment in associate within the Group Consolidated Financial Statements. The structure of Fund 8 was not finalised at 30 June 2023. As such, Fund 1 and Fund 8 are not disclosed on this slide.

Fund summary at 30 June 2023

Funds 2&3 Rest of world Launched Oct-17 Size: AUD189m		Capital called			Uncalled capital			Accumulated preferred return	Accumulated special distribution	Accumulated management fee
	AUD million	Total	Investors	Omni	Total	Investors	Omni	Investors	Investors	Omni
	Called	162.8	130.2	32.6	26.2	20.9	5.3	48.9	7.6	7.6
	Distributions	(66.6)	(66.6)	–	n/a	n/a	n/a	–	–	–
	Total AUD	96.2	63.6	32.6	26.2	20.9	5.3	48.9	7.6	7.6
Fund 4 USA Launched Apr-19 Size: USD500m		Capital called			Uncalled capital			Recycled proceeds		
	USD million	Total	Investors	Omni	Total	Investors	Omni	Total	Investors	Omni
	Called	236.1	188.8	47.3	263.9	211.1	52.8	–	–	–
	Distributions	(73.5)	(58.8)	(14.7)	–	–	–	–	–	–
	Total USD	162.6	130.0	32.6	263.9	211.1	52.8	–	–	–
AUD equivalent	245.7	196.5	49.2	398.6	319.0	79.7	–	–	–	
Fund 5 Rest of world Launched Sept-19 Size: USD500m		Capital called			Uncalled capital			Recycled proceeds		
	USD million	Total	Investors	Omni	Total	Investors	Omni	Total	Investors	Omni
	Called	167.5	133.6	33.9	332.5	266.4	66.1	–	–	–
	Distributions	(19.1)	(14.8)	(4.3)	n/a	n/a	n/a	–	–	–
	Total USD	148.4	118.8	29.6	332.5	266.4	66.1	–	–	–
AUD equivalent	224.3	179.4	44.9	502.3	402.5	99.8	–	–	–	
Fund 6 Launched Jan-17 Size: EUR150m		Capital called			Uncalled capital			Recycled proceeds		
	EUR million	Total	Investors	Omni	Total	Investors	Omni	Total	Investors	Omni
	Called	90.8	86.3	4.5	59.2	56.2	3.0	–	–	–
	Distributions	–	–	–	n/a	n/a	n/a	–	–	–
	Total EUR	90.8	86.3	4.5	59.2	56.2	3.0	50.4	47.9	2.5
AUD equivalent	149.1	141.6	7.5	97.2	92.3	4.9	82.7	78.6	4.1	
Fund 7 Launched Jul-19 Size: USD100m		Capital called			Uncalled capital			Recycled proceeds		
	USD million	Total	Investors	Omni	Total	Investors	Omni	Total	Investors	Omni
	Called	3.5	3.3	0.2	96.5	91.7	4.8	–	–	–
	Distributions	–	–	–	n/a	n/a	n/a	–	–	–
	Total USD	3.5	3.3	0.2	96.5	91.7	4.8	–	–	–
AUD equivalent	5.3	5.0	0.3	145.8	138.5	7.3	–	–	–	

Highlights

Financial results

Portfolio performance

Strategy

Annexure

Investment income

\$m	Balance sheet	Funds							Total
		1	2&3	4	5 ¹	6	7	8	
Investment income									
Investments completed in FY23	22.0	30.6	17.0	2.7	47.8	18.3	-	-	138.4
Investments completed in prior periods	19.4	-	0.7	-	-	0.2	-	-	20.3
Cash proceeds from sale of Fund 1 participation	47.7	-	-	-	-	-	-	-	47.7
Ongoing investments	-	3.7	6.8	40.3	16.9	9.3	-	-	77.0
Total FY23 income recognised	89.1	34.3	24.5	43.0	64.7	27.8	-	-	283.4
Binding conditional settlements	-	-	-	-	-	-	-	-	-
Successful judgments	-	-	-	6.8	-	24.2	-	-	31.0
Executed settlements	-	-	-	-	-	-	-	-	-
Agreed in-principle settlements	-	-	-	24.2	-	-	-	-	24.2
Total income yet to be recognised (IYTBR) ² at 30-Jun-23	-	-	-	31.0	-	24.2	-	-	55.2
Total FY23 income recognised and IYTBR at 30-Jun-23	89.1	34.3	24.5	74.0	64.7	52.0	-	-	338.6
Provisional distribution of income recognised and IYTBR ³									
- Provisional distribution attributable to OBL shareholders	89.1	-	-	14.8	12.9	3.0	-	-	119.8
- Provisional distribution attributable to NCI	-	34.3	24.5	59.2	51.8	49.0	-	-	218.8
Distribution waterfall of FY23 income recognised and IYTBR at 30-Jun-23	89.1	34.3	24.5	74.0	64.7	52.0	-	-	338.6
Income conversion rate									
EPV of investments completed in FY23 ⁴	101	497	156	1,604	822	66	-	-	3,246
Life to date income of fully completed investments in FY23	42	32	17	2	49	18	-	-	160
Income conversion rates for FY23	42%	6%	11%	0%	6%	27%	-	-	5%

1. Fund 5 is not consolidated within the Group Consolidated Financial Statements, here it is presented at 100%.

2. Subject to change and may be recognised in FY24 or later.

3. Represents indicative cashflows (excluding performance fees) anticipated to flow out of the Funds due to the income generation included in the table above. It represents the aggregate estimate of the cash distributed and yet to be distributed under the various distribution waterfalls of the Funds assuming the income is equivalent to gross cash proceeds. The Fund's capital status and waterfalls operate on a cash collection and distribution basis and do not align with the accounting treatment. Accordingly, the NCI attribution disclosed in the Group Consolidated Financial Statements will not necessarily match this.

4. Includes investments that fully completed in the period and the total income recognised over the investments' life and excludes partial completions in the period.

- \$338.6m investment income (from income recognised, income yet to be recognised and secondary market transaction) comprising:
 - \$218.8m provisionally attributable to providers of third-party capital.
 - \$119.8m provisional distribution attributable to OBL shareholders.
- Recognised investment income of \$283.4m comprises:
 - \$138.4m recognised from 33 fully completed investments which had an EPV of \$3.2bn.
 - \$97.3m recognised from partial completions and completions in previous periods.
 - \$47.7m cash proceeds from the sale of a participation in Fund 1.
- \$55.2m income yet to be recognised (IYTBR) at 30-Jun-23 relates to four substantially completed investments with conditional settlements or judgments on appeal which may be recognised in future periods:
 - corresponding EPV is \$382m.
 - one agreed in-principle Fund 4 matter which reached settlement in Aug-23 is expected to generate gross income of \$23.0m with another matter estimated to complete in FY24.
 - the remaining two matters are estimated to complete in FY25.

Non-IFRS cashflow and receivables

Consolidated Group (non-IFRS presentation)		
\$m	FY23	FY22
Proceeds from litigation investments - claims portfolio	4.8	13.4
Proceeds from litigation investments - purchase claims	0.7	6.4
Proceeds from litigation investments - intangible assets	121.8	273.3
Proceeds from disposal of subsidiaries	75.8	-
	203.1	293.1
Management and performance fees received	8.8	12.6
Interest received	1.8	0.3
	213.7	306.0
Payments to suppliers and employees	(106.0)	(74.1)
Income tax paid	(3.6)	(4.8)
Other operating activity outflows	(19.5)	(7.4)
Total cashflows from business operation	84.6	219.7
Payments for litigation investments - claims portfolio	(16.8)	(14.6)
Payments for litigation investments - purchase claims	-	-
Payments for litigation investments - intangible assets	(157.7)	(105.6)
Payments for litigation investments - capitalised overhead and employee costs	(7.8)	(6.7)
Other investing activity outflows	(2.2)	(3.9)
Total cashflows used in litigation investments	(184.5)	(130.8)
Contributions from NCI	135.9	43.6
Distributions to NCI	(93.2)	(113.3)
	42.7	(69.7)
Other financing activity outflows	15.1	(4.6)
Total cashflows from finance activities	57.8	(74.3)
Net increase/(decrease) in cash and cash equivalents	(42.1)	14.6
Net foreign exchange difference	0.1	1.8
Cash and cash equivalents at beginning of period	159.0	142.6
Cash and cash equivalents at end of period	117.0	159.0
Trade and other receivables	140.8	127.8

Non-controlling interest (NCI) in Group balance sheet

- Accelerated returns to investors from first generation funds with \$93.2m distributed to providers of third-party capital.
- Fund 6 has retained and recycled proceeds to cover the management and servicing contribution during FY23.

\$m	Fund 1	Funds 2&3	Fund 4	Fund 5 ¹	Fund 6	Fund 8	Total
Opening 30-Jun-22	(73.2)	(112.8)	(91.0)	-	(133.6)	-	(410.6)
Called during the period	(10.5)	(15.9)	(85.4)	-	(24.1)	-	(135.9)
Distributed during the period	34.2	25.0	34.0	-	-	-	93.2
Deconsolidation of subsidiary	49.5	-	-	-	-	-	49.5
Change in share of net assets attributable to NCI	4.1	(3.0)	3.7	-	2.4	-	7.2
(Profit) / loss attributable to NCI	(4.1)	(11.4)	(11.9)	-	(5.1)	-	(32.5)
Other comprehensive (income) / loss attributable to NCI	-	(0.2)	(3.7)	-	(2.4)	-	(6.3)
Closing 30-Jun-23	-	(118.3)	(154.3)	-	(162.8)	-	(435.4)
Capital remaining available to be called (NCI & parent interest)	7.6	26.2	398.6	-	97.2	-	529.6
Remaining number of cases (NCI & parent interest)	-	23	40	57	146	3	269
Remaining EPV (NCI & parent interest)	-	3,218	9,151	9,874	3,687	53	25,983
NCI distribution history							
FY18	4.3	-	-	-	-	-	4.3
FY19	18.4	4.0	-	-	-	-	22.4
FY20	57.8	10.6	3.3	-	-	-	71.7
FY21	36.2	27.0	2.1	-	-	-	65.3
FY22	80.6	-	32.7	-	-	-	113.3
FY23	34.2	25.0	34.0	-	-	-	93.2
Total distributions	231.5	66.6	72.1	-	-	-	370.2

1. Fund 5 is not consolidated within the Group Consolidated Financial Statements, here it is presented at 100%.

Developing regulatory landscape

US

- Some US courts have set rules requiring disclosure of litigation funding arrangements. Omni Bridgeway continues to review and consider the implications of those rules.
- The US Chamber of Commerce's Institute for Legal Reform continues to lobby for litigation finance legislation at the federal and state level. Dispute funders, including Omni Bridgeway, monitor and respond via ILFA to maintain a level playing field.
- The US Government Accountability Office (GAO) initiated an inquiry into the US litigation funding industry. This non-partisan branch of the federal government provides research reports to Congress. Representatives from ILFA (including Omni Bridgeway) participated in the inquiry. The GAO report was published in December 2022. It surveyed the third-party litigation finance market, discussed pros and cons and distinguished between commercial and consumer funding. The report made no specific recommendations.

Europe

- In September 2022, the EU Parliament approved a Committee on Legal Affairs report into litigation funding and requested the European Commission to propose a Directive.
- Proposed rules included a duty on claimants to disclose third-party funding and a fee cap on funders. If enacted, Member States would then have time to implement the Directive in their domestic law. In June 2023, ILFA published a report which criticised the proposed reforms.
- In June 2023, ILFA published a report which criticised the proposed reforms. In late June 2023, it was reported that the Commission has planned to conduct a study of the existing European litigation funding landscape before implementing any new rules.
- In July 2023, the German Federal Parliament (Bundestag) passed a Bill to implement the EU Collective Redress Directive. Aspects of the Bill have been subject to criticism, including late changes which restrict the amount that a litigation funder may agree to receive from the proceeds of a successful claim to 10%. Although these limitations will have little direct impact on our business, we will monitor any future impact of the changes.

UK

- In late July 2023, in *PACCAR Inc v Competition Appeal Tribunal*, the UK Supreme Court overturned earlier decisions in the case and held that the litigation funding agreements (LFAs) at issue were damages-based agreements (DBA) within the meaning of the relevant legislation in England. As a result, the LFAs were subject to the DBA Regulations 2013 which set out certain requirements for an agreement to be lawful and enforceable.
- It was accepted that the LFAs considered by the UK Supreme Court were non-compliant with the DBA Regulations, and therefore unenforceable.
- Omni Bridgeway, through its highly diversified investment portfolio, has very limited exposure to this development. The DBA Regulations are specific to English litigation and arbitration with particular pricing structures and have little or no impact on our other markets, including continental Europe, the Americas or APAC. We do not anticipate any material impact on existing investments and remain confident that the UK will be a key market for litigation funding.

Australia

- Following the change of the federal government in May 2022, a more favourable regulatory landscape emerged.
- In June 2022, the Federal Court of Appeal held that a funded class action is not a MIS (managed investment scheme).
- In December 2022, the federal government enacted regulations that exempt litigation funders from holding an Australian Financial Services Licence (AFSL) and other financial services regulatory requirements.

Assumptions relating to the provisional attribution of implied embedded value, estimated management fees and potential performance fees

IEV assumptions and notes – refer to slides 10 and 15

The attribution of implied embedded value (IEV) between OBL equity and non controlling interests (NCI) has been prepared on the basis of the following underlying assumptions:

- All unconditionally funded investments in the Group's investment portfolio at the date stated (Portfolio Investment(s)) complete in the selected Possible Completion Period (PCP).
- All Portfolio Investments are completed at their full estimated portfolio value (EPV).
- The income received by the Omni Bridgeway funding entity upon the completion of a Portfolio Investment reflects the long term conversion rate (LTCR) (which includes losses) and hence equals the full IEV of an investment.
- The residual capital to be deployed in Funds 2&3 is deployed in equal portions during FY24 and FY25.
- For Funds 4 and 5 the attribution is split solely in proportion to capital commitments.
- For Fund 6 the attribution to OBL equity reflects the historic blended average proportion of proceeds received by OBL equity (excluding performance fees).
- FX rates are assumed to remain constant across the periods.
- Performance fees in Funds 4, 5 and 6 have been excluded from the attribution to OBL and hence any performance fees earned will see an IEV attribution shift from NCI to OBL equity.

The sensitivity analysis provided uses the following assumptions:

- IEV is adjusted to reflect variations in the income conversion rate from the LTCR of 15%. The selected sensitivity rates are 10% and 20%.
- EPV of material impaired investments are excluded from EPV with commensurate flow-on to IEV and attribution.
- PCP on all Portfolio Investments is delayed by 12 months. Duration risk has traditionally been addressed through a time based pricing escalator. Historically these capped out at a certain level, leaving the Group exposed to further delays. We have sought to address the risk by incorporating some additional IRR protection provisions. The 12 month delay sensitivity does not incorporate the effects of these duration protections and assumes the income is the IEV at whatever time it is received.

Estimated portfolio value (EPV) assumptions:

- EPV includes all Portfolio Investments, irrespective of impairment provided, the Group believes there are positive prospects of ultimate success.
- Conditionally funded and IC approved investments are not included in the EPV.

Possible completion period (PCP):

- PCP is a dynamic concept, subject to regular review to take account of each investment's circumstances.
- It is to be expected that the PCP for some investments will be adjusted at each reporting date.
- PCP is not necessarily the same as anticipated IFRS income recognition period.

Estimated management fee assumptions – refer to slides 10 and 11

- Funds 4 and 5 earn management fees of up to 2.15% of external capital deployed as well as additional service fees.
- Includes Fund 6 management and servicing contribution which is recognised as a equity contribution and anticipated service fees from Fund 8.
- This approximation of management fees assumes that the net deployed capital grows in FY24 at approximately 17%. In practice, net deployed capital may vary over a given period, including delays or accelerations of investment completions or expenditure of investment budgets.

Potential performance fees – refer to slides 10 and 12

- To determine the potential performance fees in Fund 4 and Fund 5, it is assumed that the income received by the applicable Omni Bridgeway funding entity equals the full IEV of an investment and that investments complete in line with the Group's historical ROIC which is used to divide the IEV between the return of investor capital and the portfolio investment profit upon which performance fees are payable.
- The respective Fund 4 and Fund 5 performance fee waterfalls (see slide 16 for a summary of the performance fee calculation and waterfall) are then used to calculate the potential range of performance fees depending upon the applicable IRR achieved across the relevant investment portfolios
- Past performance is not necessarily an indicator of future performance. This analysis is based on the hypothetical scenario of Fund 4 and Fund 5 investments completing at a normalised EPV conversion rate of 15% to their respective EPV at 30 June 2023, at an assumed ROIC. In practice, the portfolios will complete over multiple time periods with metrics different to those assumed.

Disclaimer

- The material in this presentation has been prepared by Omni Bridgeway (OBL) and is general background information about Omni Bridgeway's activities. The information is given in summary form and does not purport to be complete.
- A number of terms used in this presentation including: ROIC, EPV, IEV, net cash generation, operational cash expenditure, success rate on dollar weighted average, IRR and actual and budgeted commitments are categorised as non-IFRS information prepared in accordance with ASIC Regulatory Guidance 230 – Disclosing non-IFRS financial information, issued in December 2011. This information has not been audited or reviewed by BDO unless expressly stated. For further commentary and analysis refer to Omni Bridgeway's 2023 Annual Report, see the Investors section of our website.
- Capitalised terms not defined within this presentation have the meanings given to such terms in OBL's glossary which can be found at <https://omnibridgeway.com/investors/omni-bridgeway-glossary> and should be consulted for further detail.
- This presentation contains certain forward-looking statements that can generally be identified using forward looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target” and other similar expressions. Estimates of, indications of, and guidance or outlook on, future earnings or financial position or performance are also forward looking statements. Forward looking statements involve risks and uncertainties. Forward looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Forward looking statements involve known and unknown risks, uncertainties, assumptions, and contingencies which are subject to change without notice, as are statements about market and industry trends which are based on interpretations of current market conditions. Actual results, performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. Except as required by law or regulation, OBL disclaims all obligations to update publicly any forward looking statements, whether as a result of new information, future events, or results or otherwise.
- This presentation is provided for general information purposes. The information in this presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase any Omni Bridgeway securities. Neither the information in this presentation nor any part of it shall form the basis of or be relied upon in connection with any future offer of Omni Bridgeway securities or act as an inducement to enter into any contract or commitment whatsoever.
- To the maximum extent permitted by law, no representation or warranty is given, express or implied, as to the accuracy of the information contained in the presentation.
- The information in this presentation is not investment advice and has been prepared without taking into account your investment objectives, financial situation or particular needs (including financial and taxation issues). It is important that you read and consider the terms of any Omni Bridgeway securities in full before deciding to invest in such securities and consider the risks that could affect the performance of those securities.
- If you have any questions, you should seek advice from your financial adviser or other professional adviser before deciding to invest in Omni Bridgeway securities.
- By providing the material in this presentation Omni Bridgeway is not in any way making forecasts, predictions or providing earnings guidance and nothing in this presentation should be relied on as doing so.
- All figures are in Australian Dollars (AUD, A\$) unless otherwise stated.
- **US Ownership Restriction** – the ordinary shares of Omni Bridgeway are subject to ownership restrictions applying to residents of the United States. For further information, see the Investors section of our website or click <https://omnibridgeway.com/investors/us-ownership-restriction>

Americas

Chicago +1 872 260 2057 500 West Madison Street Suite 1000 Chicago IL 60661 United States	Minneapolis +1 612 488 9211 60 South 6th Street Suite 2800 Minneapolis MN 55402 United States	Montreal +1 514 257 6971 60 rue St-Jacques Bureau 401 Montréal QC H2Y 1L5 Canada	Montevideo +1 514 257 6971 Uruguay
Dallas +1 212 488 5331 United States	New York +1 212 488 5331 437 Madison Avenue 36th Floor New York NY 10022 United States	Toronto +1 416 583 5720 250 The Esplanade Suite 127 Toronto ON M5A 1J2 Canada	
Houston +1 713 965 7919 LyondellBasell Tower 1221 McKinney Street Suite 2860 Houston TX 77010 United States	San Francisco +1 415 231 0363 50 California Street Suite 2930 San Francisco CA 94111 United States		
Los Angeles +1 213 550 2687 555 W. Fifth Street Suite 3310 Los Angeles CA 90013 United States	Washington, D.C. +1 771 213 5181 2101 L Street, N.W. Suite 925 Washington, D.C. 20037 United States		
Miami +1 786 891 2228 United States			

Asia-Pacific

Melbourne +61 3 9913 3301 Level 3 Bourke Place 600 Bourke Street Melbourne VIC 3000 Australia	Hong Kong +852 3978 2629 Level 27 World-Wide House 19 Des Voeux Road Central Central, Hong Kong
Perth +61 8 9225 2300 Level 10 66 St Georges Terrace Perth WA 6000 Australia	Singapore +65 6813 2647 Level 13-03 6 Battery Road Singapore 049909
Sydney +61 2 8223 3567 Level 7 35 Clarence Street Sydney NSW 2000 Australia	Auckland +64 277 470 369 Commercial Bay Tower Level 17 11-19 Customs Street West Auckland 1010 New Zealand

Europe, Middle East & Africa

Amsterdam +31 70 338 4343 Schiphol Boulevard 121 1118 BG Schiphol Amsterdam The Netherlands	London +44 203 968 6061 Holborn Gate 330 High Holborn London WC1V 7QH United Kingdom	Dubai +971 4 514 4608 Unit 1905, Level 19 Index Tower Dubai International Financial Centre 507152 Dubai United Arab Emirates
Cologne +49 221 801155-0 Gereonstr. 43-65 50670 Cologne Germany	Madrid +31 70 338 4343 Spain	
Geneva +41 22 818 6300 Rue de la Rôtisserie 4 1204 Geneva Switzerland	Milan +39 339 448 3907 Via Fatebenefratelli, 5 20121 Milano MI Italy	
	Paris +33 6 5159 4359 31 rue du Colisée 75008 Paris France	